A Study to Evaluate the Efficacy and Safety of AD-224

Addpharma

Status and phase: Enrolling; Phase 3

Conditions: Hypertension,Essential

Treatments: Drug: Placebo of AD-224A; Drug: AD-224B; Drug: AD-224C; Drug: AD-224A; Drug: Placebo of AD-224C; Drug: Placebo of AD-224B

Study type: Interventional

Funder types: Industry

Identifiers

NCT06291207

AD-224P3

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of AD-224

Full description

Condition or disease : Essential Hypertension

Enrollment: 252 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Patients with Essential Hypertension
• Other inclusions applied

Exclusion criteria

• Patient with Secondary Hypertension
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

252 participants in 3 patient groups

AD-224A

Experimental group

Description:

AD-224A+Placebo of AD-224B+Placebo of AD-224C

Treatment:

Drug: Placebo of AD-224B

Drug: Placebo of AD-224C

Drug: AD-224A

AD-224B

Experimental group

Description:

Placebo of AD-224A+AD-224B+Placebo of AD-224C

Treatment:

Drug: Placebo of AD-224C

Drug: AD-224B

Drug: Placebo of AD-224A

AD-224C

Active Comparator group

Description:

Placebo of AD-224A+Placebo of AD-224B+AD-224C

Treatment:

Drug: Placebo of AD-224B

Drug: AD-224C

Drug: Placebo of AD-224A